SCHEDULE 13G/A: Blue Owl Capital Discloses 3.42% Stake in Biomea Fusion

Blue Owl Capital Holdings LP has reported a 3.42% beneficial ownership stake in Biomea Fusion, Inc., primarily through warrants.

Summary

• Blue Owl Capital Holdings LP (the "Reporting Person") has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Biomea Fusion, Inc.
• The filing reports beneficial ownership of 2,500,000 shares of Biomea Fusion, Inc. Common Stock.
• These shares represent 3.42% of the class of securities.
• The reported securities are issuable upon the exercise of warrants, with each warrant acquiring one share of Common Stock.
• The percentage of class is calculated based on 70,703,639 shares of Common Stock outstanding as of October 31, 2025, as reported in the Issuer's 10-Q filed on August 8, 2025, plus the 2,500,000 shares from the warrants.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing disclosing an ownership stake. It doesn't inherently convey positive or negative sentiment about the company's performance, but rather a factual statement of an institutional investment.

Positives

• A significant institutional investor, Blue Owl Capital Holdings LP, holds a stake, potentially indicating confidence in Biomea Fusion, Inc.
• The stake is held through warrants, which could provide future capital to Biomea Fusion, Inc. upon exercise.

Risks

• The value of the warrants, and thus the beneficial ownership, is subject to the future stock price performance of Biomea Fusion, Inc.
• The exercise of warrants could lead to dilution for existing shareholders if the shares are newly issued.

Future Outlook

NA

Industry Context

This filing indicates continued institutional investor interest in the biotechnology or pharmaceutical sector, specifically in companies like Biomea Fusion, Inc. The investment by Blue Owl Capital, a prominent alternative asset manager, suggests a strategic position in the company, aligning with broader trends of institutional capital deployment into growth-oriented life sciences firms.

Stakeholder Impact

• Shareholders: The disclosure of an institutional investor's stake can sometimes be viewed positively, indicating confidence. Potential future dilution if warrants are exercised and new shares are issued.
• Company (Biomea Fusion): The existence of warrants represents potential future capital if exercised.

Next Steps

• Biomea Fusion, Inc. will continue its operations, potentially benefiting from the future exercise of these warrants.
• Blue Owl Capital Holdings LP will continue to monitor its investment in Biomea Fusion, Inc.

Key Dates

Keywords

Biomea Fusion, Blue Owl Capital, Schedule 13G, beneficial ownership, warrants, common stock, institutional investment, SEC filing, BMEA